Literature DB >> 14670583

Anti-HSV activity of lactoferricin analogues is only partly related to their affinity for heparan sulfate.

Håvard Jenssen1, Jeanette Hammer Andersen, Lars Uhlin-Hansen, Tore Jarl Gutteberg, Øystein Rekdal.   

Abstract

Earlier studies have shown that the heparan sulfate (HS) on the cell surface acts as a receptor for herpes simplex virus (HSV). We have recently shown that bovine lactoferricin (LfcinB), a small part of the milk protein lactoferrin, inhibits HSV-1 and HSV-2 infection, probably by blocking the entry of the virus. The human homologue (18-42), which shares 36% sequence similarity with LfcinB (17-41), displayed much lower antiviral activity. In the present study, a set of cyclic and linear human and bovine Lfcin derivatives were constructed to investigate the relation between their affinity to HS and chondroitin sulfate (CS) and their antiviral activity against HSV-1 and HSV-2. The lactoferrin (LF) proteins and several of the Lfcin derivatives exhibited similar affinity for HS, but the LF proteins possess a much higher antiviral activity than the smaller peptides. Our structure-activity relationship studies on the Lfcin derivates confirmed that affinity for HS, that was correlated to the net positive charge, is an important factor, but does not well predict the antiviral activity. Structural parameters such as hydrophobicity, molecular size, spatial distribution of charged and lipophilic amino acids, and the cyclic structure of Lfcin also seem to be important factors to govern antiviral activity against HSV.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14670583     DOI: 10.1016/j.antiviral.2003.09.001

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  29 in total

Review 1.  Peptide antimicrobial agents.

Authors:  Håvard Jenssen; Pamela Hamill; Robert E W Hancock
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

2.  Addition of a C-terminal cysteine improves the anti-herpes simplex virus activity of a peptide containing the human immunodeficiency virus type 1 TAT protein transduction domain.

Authors:  Hermann Bultmann; Jeremy Teuton; Curtis R Brandt
Journal:  Antimicrob Agents Chemother       Date:  2007-01-29       Impact factor: 5.191

3.  Inhibition of herpes simplex virus type 1 infection by cationic beta-peptides.

Authors:  Radeekorn Akkarawongsa; Terra B Potocky; Emily P English; Samuel H Gellman; Curtis R Brandt
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

4.  Human lactoferricin is partially folded in aqueous solution and is better stabilized in a membrane mimetic solvent.

Authors:  Howard N Hunter; A Ross Demcoe; Håvard Jenssen; Tore J Gutteberg; Hans J Vogel
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications.

Authors:  Berthony Deslouches; Kazi Islam; Jodi K Craigo; Shruti M Paranjape; Ronald C Montelaro; Timothy A Mietzner
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 6.  Therapeutic and prevention strategies against human enterovirus 71 infection.

Authors:  Chee Choy Kok
Journal:  World J Virol       Date:  2015-05-12

7.  Immunobiology of herpes simplex virus and cytomegalovirus infections of the fetus and newborn.

Authors:  William J Muller; Cheryl A Jones; David M Koelle
Journal:  Curr Immunol Rev       Date:  2010

8.  Bovine lactoferricin inhibits basic fibroblast growth factor- and vascular endothelial growth factor165-induced angiogenesis by competing for heparin-like binding sites on endothelial cells.

Authors:  Jamie S Mader; Daniel Smyth; Jean Marshall; David W Hoskin
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

9.  The Importance of Heparan Sulfate in Herpesvirus Infection.

Authors:  Christopher D O'Donnell; Deepak Shukla
Journal:  Virol Sin       Date:  2008-12-01       Impact factor: 4.327

10.  The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells.

Authors:  Bodil Fadnes; Oystein Rekdal; Lars Uhlin-Hansen
Journal:  BMC Cancer       Date:  2009-06-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.